LUIS ALBERTO MENCHÉN VISO-rekin lankidetzan egindako argitalpenak (3)

2017

  1. Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis

    Inflammatory Bowel Diseases, Vol. 23, Núm. 8, pp. 1394-1402

2011

  1. Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experience

    Gastroenterologia y Hepatologia, Vol. 34, Núm. 7, pp. 443-448

2008

  1. Open-label infliximab therapy in Crohn's disease: A long-term multicenter study of efficacy, safety and predictors of response

    Gastroenterologia y Hepatologia, Vol. 31, Núm. 7, pp. 421-426